Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 5/20 | 0.48 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91478 | 0.93 | CTSK (0.58) | CTSKCDK4CDK2CDK1CCNB1 | |
| SCHEMBL18677322 | 0.92 | CDK1 (0.54) | CTSKCDK4CDK2CDK1CCNB1 | |
| SCHEMBL24065221 | 0.92 | CDK1 (0.54) | CTSKCDK4CDK2CDK1CCNB1 | |
| SCHEMBL91484 | 0.91 | CTSK (0.60) | CTSKCDK4CDK2CDK1CCNB1 | |
| SCHEMBL15830033 | 0.88 | MAPK1 (0.62) | HRH4MAPK1MAPK8MAPK9MAPK10 | |
| SCHEMBL6508763 | 0.88 | IKBKB (0.58) | CTSKCDK4CDK2CDK1CCNB1 | |
| SCHEMBL12367075 | 0.87 | IKBKB (0.61) | CDK4CDK2CDK1CCNB1CCNA2 | |
| SCHEMBL14176051 | 0.86 | MAPK8 (0.56) | CDK4CDK2CDK1CCNB1CCND1 | |
| SCHEMBL12367079 | 0.81 | BRD4 (0.50) | CTSKCDK4CDK2CDK1CCNB1 | |
| SCHEMBL13693348 | 0.80 | BRD4 (0.52) | CDK4CDK2CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | disclosed |
| US-9657009-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9296745-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150284382-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | IRAK4, IRAK3, IRAK2 | CTSK 3447/4885CDK4 59/4885CDK2 349/4885 |
| US-20150284382-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | CTSK 3350/4885CDK4 48/4885CDK2 292/4885 |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | CTSK 3925/4885CDK4 1784/4885CDK2 693/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CTSK 1606/4885CDK4 12/4885CDK2 20/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CTSK 2315/4885CDK4 20/4885CDK2 34/4885 |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | CTSK 3447/4885CDK4 59/4885CDK2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.